Navigation Links
Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Date:7/23/2009

nnounced in due course.

The Company has sufficient cash at hand to fund operations into August, however the Company will need to raise additional capital to fund its clinical trials and other operating activities, and repay indebtedness in due course. Shareholders should be aware that if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is in a large Phase II clinical trial in GBM, with 13 clinical sites across the U.S. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future securities registrations or other filings with the U.S. Securities and Exchange Commission ("SEC"), future treatment of patients with GBM using DCVax(R)-Brain, and other future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such a
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
2. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
3. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Oncothyreon to present at Invest Northwest 2009
6. Sirius Genomics to Present at Invest Northwest Conference
7. Northwest Biotherapeutics Secures $700,000 Equity Financing
8. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
9. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
10. Northwest Secures US$1.65 Million Debt Financing
11. Northwest Secures US$1.0 Million Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Antipsychotic Agent with Less Potential for ... and Metabolic Risks, SAN DIEGO, July 29 ... the United States Patent and,Trademark Office (USPTO) issued a ... broad coverage for a pharmaceutical,composition of zonisamide in combination ...
... up to 50% sucrose reduction while maintaining the sweet taste ... ... July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), a leading ... ingredients for the food, beverage,and ingredient supply industries, announced today that ...
... July 29 Zenobia Therapeutics, Inc.,(Zenobia) announced ... Development,Initiative award from The Michael J. Fox ... research with potential to,fundamentally alter the course ... Dr. Christopher Ross of Johns Hopkins University,Zenobia ...
Cached Biology Technology:OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced ... the APAC Region 2015-2019"  report to their offering. ... this market is advances in technology. With continuous ... biometric solutions to the latest standard that meets ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... has shown a normalizing effect of platelet-endothelial cell alterations ... Cyclooxygenase 2 inhibition. This study, ... is described in a research article to be published ... of Gastroenterology. Portal hypertension is a major complication ...
... U.S. Department of Energy,s Argonne National Laboratory is ... toward the goal of creating a cleaner Beijing ... Games and beyond. Recently, DOE and ... five-year agreement aimed at promoting large scale deployment ...
... an Indiana University environmental science professor and several colleagues ... has the potential to harm aquatic ecosystems. The study ... Proceedings of the National Academies of Sciences . ... professor in the IU School of Public and Environmental ...
Cached Biology News:Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension 2Argonne helps China create cleaner Beijing for 2008 Olympics 2Study shows genetically engineered corn could affect aquatic ecosystems 2Study shows genetically engineered corn could affect aquatic ecosystems 3
... medium was originally formulated to support the ... emperor gum moth,Antherea eucalypti. The medium is ... closely resembleAnthereahemolymph. The cell lines established by ... continuous lines developed. The basal medium, when ...
... all Programmable and Digital Orbital Shaker. Our durable, ... to make every day use even easier. This ... up to 4 different programs. Its easy recall ... Furthermore, the VSOS-4P has a pulse operation for ...
... MONOLIGHT 3096 Microplate Luminometer has been ... bioluminescence and for,all measurements of glow ... reactions where the light remain nearly ... as well as for very fast ...
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
Biology Products: